METSERA INC (MTSR) Stock News
NASDAQ:MTSR - Nasdaq - US59267L1070 - Common Stock - Currency: USD
MTSR Latest News, Press Relases and Analysis
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at the gap up and gap down stocks in today's session.
Get insights into the top gainers and losers of Monday's pre-market session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company...
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results
Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would allow patients to go from weekly to monthly dosing.
Mentions: LLY
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential...
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional...
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected...
Metsera to Present at Bank of America 2025 Global Healthcare Conference
Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company...
Pfizer Setback Spurs Rise in Obesity Developers on M&A Hopes
Shares of several biotechs developing obesity drugs rallied on Monday after Pfizer Inc. halted development of its closely-watched experimental pill, as investors bet that the setback could spur dealmaking by Pfizer.
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning...
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation...
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.